Drugs / Aflunov
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Aflunov | — | 2010-11-28 | europa.eu ↗ |
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00620815 | Nov 2007 → Jan 2008 | influenza | Novartis Vaccines | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00814385 Comparator | Nov 2008 → Sep 2013 | influenza | University Hospitals, Leicester | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aflunov | “One dose of the Aflunov (A) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed by Tetravalent influenza vaccine (T) on day 22.” NCT00620815 ↗ |
| Modality | Vaccine | “Pandemic influenza vaccine” NCT00620815 ↗ |
| Route | Intramuscular | “intramuscular (IM)” NCT00814385 ↗ |